RU 41,656 does not reverse the scopolamine-induced cognitive deficit in healthy volunteers.

Area of Science:

• Neuroscience
• Pharmacology
• Cognitive Science

Background:

• Scopolamine is known to induce memory and attention impairments.
• RU 41,656 is being investigated for potential cognitive-enhancing effects.

Purpose of the Study:

• To evaluate the potential of RU 41,656 to antagonize scopolamine-induced cognitive disturbances.
• To assess the effects of RU 41,656 on memory and attention in healthy volunteers.

Main Methods:

• A 3-period, placebo-controlled, double-blind, cross-over study.
• 12 healthy young volunteers received scopolamine (0.6 mg s.c.) and RU 41,656 (10 mg oral).
• Cognitive function was assessed using objective tests (e.g., Buschke selective reminding, CFF) and subjective measures.

Main Results:

• Scopolamine induced significant anterograde amnesia and sedative effects.
• RU 41,656 did not significantly counteract the amnesic or sedative effects of scopolamine.
• No significant differences were observed in objective or subjective measures between RU 41,656 treatment and placebo.

Conclusions:

• RU 41,656, at the tested dose, does not appear to possess pro-cognitive or anti-amnesic properties against scopolamine-induced impairment.
• Further research may be needed to explore other dosages or different cognitive domains.